

Integrated Biosensor for Rapid and Point-Of-Care Sepsis Diagnosis

Jouha Min, Maria Nothing, Ben Coble, Hui Zheng, Jongmin Park, Hyungsoon Im,
Georg F. Weber, Cesar M. Castro, Filip K. Swirski, Ralph Weissleder, and Hakho Lee

ACS Nano, **Just Accepted Manuscript** • DOI: 10.1021/acsnano.7b08965 • Publication Date (Web): 13 Mar 2018

Downloaded from <http://pubs.acs.org> on March 15, 2018

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



Integrated Biosensor for Rapid and Point-Of-Care Sepsis Diagnosis

Jouha Min,^{1,2} Maria Nothing,³ Ben Coble,¹ Hui Zheng,⁴ Jongmin Park,^{1,2} Hyungsoon Im,^{1,2} Georg F. Weber,³ Cesar M. Castro,^{1,5} Filip K. Swirski,¹ Ralph Weissleder,^{1,2,6*} Hakho Lee^{1,2*}

- 1. Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114
- 2. Department of Radiology, Massachusetts General Hospital, Boston, MA 02114
- 3. Department of Surgery, University Hospital of Erlangen, Erlangen, Germany
- 4. Biostatistics Center, Massachusetts General Hospital, Boston, MA 02114
- 5. Department of Medicine, Massachusetts General Hospital, Boston, MA 02114
- 6. Department of Systems Biology, Harvard Medical School, Boston, MA 02115

Keywords: sepsis, organ failure, IL-3, point-of-care, electrochemical sensing

ABSTRACT

Sepsis is an often fatal condition that arises when the immune response to an infection causes widespread systemic organ injury. A critical unmet need in combating sepsis is the lack of accurate early biomarkers that produce actionable results in busy clinical settings. Here, we report the development of a point-of-care platform for rapid sepsis detection. Termed IBS (integrated biosensor for sepsis), our approach leverages i) the pathophysiological role of cytokine interleukin-3 (IL-3) in early sepsis, and ii) a hybrid magneto-electrochemical sensor for IL-3 detection. The developed platform produces test results within 1 hour from native blood samples, and detects IL-3 at a sensitivity of <10 pg/mL; this performance is >5-times faster and >10-times more sensitive than conventional enzyme-linked immunosorbent assays, the current gold standard. Using clinical samples, we show that high plasma IL-3 levels are associated with high organ failure rate and thus greater risk of mortality, confirming the potential of IL-3 as a sepsis diagnostic biomarker. With further system development (e.g., full automation, data security measures) and rigorous validation studies, the compact and fast IBS could become a practical clinical tool for timely diagnosis and proactive treatment of sepsis.

Sepsis is the leading cause of death from infection, especially if not identified and treated promptly.^{1–3, 4} In the US alone, sepsis is responsible for more than 250,000 deaths annually.^{5, 6} with the mortality rate reaching up to 50%. It also incurs a considerable financial burden, accounting for > \$20 billion of total US hospital costs.^{1, 7} Incidence continues to rise, because of the emergence of drug-resistant pathogens, growing elderly population, and the increased use of immunosuppression.⁸ Sepsis requires immediate medical treatment, ideally within hours of the disease onset, because of its dynamic and acute nature.^{9–11} Unfortunately, current diagnostic methods (e.g., measurement of vital signs or scores (qSOFA) to determine onset of the systemic inflammatory response syndrome) often fail to meet the required speed or accuracy.¹² Certain serum biomarkers such as calcitonin and uPAR have been evaluated but lack the necessary sensitivity.^{13–15} Since most patients have an underlying infection, blood cultures is a necessary component of medical management. Positive results, however, could take a long time (12 hours to a few days) to show up, and may not discriminate between local infection and progression to sepsis; culture-positive sepsis is observed in only 30% to 40% of cases.¹ It is generally accepted that earlier recognition and focused management improves the outcomes in sepsis.

In prior studies, we had identified a previously unknown indicator to sepsis.^{16–18} Particularly, we have identified the inflammatory factor interleukin-3 (IL-3) as an independent predictor of septic shock and death being produced by innate response activator (IRA) B cells following TLR activation. IL-3 operates upstream of key cytokines including TNF α , IL-1 β and IL-6 (**Scheme 1**). In a proof-of-concept study, we showed that high IL-3 levels in septic patients are associated with high mortality.¹⁷ A recent study further confirmed the role of IL-3 in the immune regulation and potential response to corticosteroids during sepsis.¹⁹ Translating this discovery into a clinically viable test, however, still remains a difficult task, largely due to the lack of fast, easy-to-use, and sensitive platforms that could overcome the long assay time and complexity of a standard enzyme-linked immunosorbent assay (ELISA). Alternative approaches based microfluidic chips,^{20, 20–22} centrifugal disc,²³ glass capillary²⁴ and microbeads^{25–27} have been demonstrated for rapid quantification, but their practicality in clinical settings is still limited due to the requirement of i) sophisticated fluidic design and controls (e.g., microfluidics), and ii) large and/or expensive equipments such as a fluorescent microscope or a plate reader for signal detection.^{26, 28, 29}

Here, we report the development of a point-of-care (POC) approach, termed IBS (integrated biosensor for sepsis), for rapid and accurate sepsis diagnosis. Specifically, we advanced a portable biosensor consisting of a disposable kit for blood processing and an electrical detection system. The kit is used to capture IL-3 on magnetic beads and label it for electrochemical reaction; the detector then measures electrical currents for IL-3 quantification. This strategy has practical advantages: i) target protein (IL-3) can be enriched directly from blood; ii) the assay achieves high detection sensitivity through magnetic enrichment and enzymatic signal amplification; iii) based on the electrical measurements, the sensor can be easily miniaturized and easy-to-use. When benchmarked against standard ELISA, IBS was 10-fold more sensitive and 5-fold faster, producing diagnostic results in an actionable time frame (<1 hour). Further testing with human clinical samples ($n = 62$) affirmed IL-3 as a potent diagnostic and prognostic biomarker; detection sensitivity and specificity were 91.3% and 82.4% respectively, and high IL-3 levels at sepsis onset were significantly correlated with patient survival.

RESULTS AND DISCUSSION

IBS platform

The IBS assay starts by extracting the target protein IL-3 through immunomagnetic enrichment. The captured protein is then subsequently labeled with detection antibodies and oxidizing enzyme (horseradish peroxidase, HRP). Finally, the beads are mixed with chromogenic electron mediators (3,3',5,5'-tetramethylbenzidine, TMB); the enzyme catalyzes the oxidation of TMB and the reduction of H₂O₂. The oxidized TMB is then reduced by receiving electrons from the electrode, which generates electrical current as an analytical read out. Using magnetic beads allows for direct and fast extraction of IL-3 from blood samples. We could also amplify the signal (~70%) by magnetically concentrating HRP-bearing beads on top of the electrode.³⁰ A small disc magnet was placed underneath the electrode position.

To streamline sample processing, we designed a magnetic assay tool that consisted of a magnetic pipette and a tray of linear wells. The pipette had a sheathed magnet attached to a mechanical plunger (**Fig. 1B**). This device allowed for quick collection and release magnetic beads. The linear tray was prepared as a near-complete package with all the required reagents, reflecting the assay procedure. The preloaded immunomagnetic beads and antibodies were stable for about 2 weeks when stored at 4 °C. We added the media (0.1% BSA solution) to the wells immediately before testing. We then loaded blood samples, mixed with immunomagnetic beads, to the first well, and sequentially transferred magnetic beads using the magnetic pipette. This unit rendered the assay simple, cost-effective and self-contained; no additional equipment (e.g., centrifuge) was needed for sample preparation. For a longer shelf life, the preloaded reagents can be lyophilized and reconstituted at the time of use; we previously observed that lyophilized reagents retained their reactivity at least up to 4 weeks.^{31, 32}

We further combined sample processing and signal detection into a single monolithic device (**Fig. 1C**, and **Fig. S1**) to promote portable, user-friendly operations. The integrated IBS device had the following features. i) A miniaturized electronic device was designed (**Fig. S2**), comprising potentiostats capable of measuring a wide range of current ($\pm 7.5 \mu\text{A}$), a microcontroller unit for signal processing, and a bluetooth module for wireless communication. ii) A latch mechanism was developed to connect an electrode to the system. Compared to commonly-used card-edge connectors that require forceful insertion, the latch method enabled a quick slip-loading of electrodes. iii) A smartphone was docked to the system, and functioned as a touch-screen interface. We also designed a smartphone app for system control and data storage (**Fig. S3**). The resulting IBS device was a standalone handheld unit, measuring electrical currents and displaying IL-3 concentrations. The cost of goods was about \$50 for the IBS reader; and the reagent cost was ~\$5 per test (**Table S1**). These prices are expected go down with a scale-up production, which will give IBS competitive cost advantages over ELISA (\$11) or lateral flow strips (\$10–20).

Assay optimization

We applied the chronoamperometry method for signal detection. The electrical current generated from TMB reduction was monitored, while a reduction potential was applied to a working electrode (**Fig. 2A**). The current level (I) reached a plateau within 1 min after the reduction potential was applied. We averaged the current level (I) from 40 to 45 seconds as a representative value.

We prepared a pair of magnetic beads (2.7 μm in diameter): one conjugated with antibodies against IL-3 (IL-3 beads) and the other with beads conjugated with antibodies against isotype matched IgG (IgG beads). The average number of antibodies per bead was $\sim 4 \times 10^5$ (**Fig. S4**). Even when subjected to basic or acidic conditions, the beads retained antibodies, which confirmed the formation of covalent bonding between beads and antibodies (**Fig. S4**). Prepared beads were loaded in the linear trays, one bead type per tray, and samples were processed simultaneously. The analytical metric was the net current difference $\Delta I = I_{\text{IL-3}} - I_{\text{IgG}}$, where $I_{\text{IL-3}}$ and I_{IgG} were the current levels with IL-3 and IgG beads, respectively. We also compared signal levels with differently sized beads (diameters of 2.7 and 4.5 μm), and found that the measured signal levels were similar when the total surface area of beads was matched (data not shown). We opted to use 2.7 μm beads, as the bigger ones tended to sediment and required longer time for magnetic isolation. The optimal bead concentration for high signal was $\sim 5.0 \times 10^7$ beads/mL (**Fig. S5**).

We further optimized the assay protocol with the goal of minimizing the sampling time while maximizing sensitivity. Samples were prepared by spiking IL-3 into human plasma. We generated standard curves, varying the IL-3 extraction time with magnetic beads (**Fig. 2B**). We observed similar results between 30 min and 12 hour incubation. For a given incubation time, the extraction at room temperature was as efficient as at 37 $^{\circ}\text{C}$. Further testing showed that subsequent assay steps (*i.e.*, labeling of detection antibodies and HRP enzyme) were efficient for 10 min incubation each. The sample-to-detection time, measured from the IL-3 extraction from patient sample to the sensor readouts, was ~ 50 min, which is >7 -times faster than ELISA (7 hours).

Assay characterization

We next examined the assay robustness. We spiked IL-3 (1 ng/mL) in different biological fluids (PBS with 1% BSA, single donor human plasma, serum, and whole blood) and performed the IBS assay (**Fig. 2C**). The signal-to-noise ratio (SNR, given by signal divided by 3-times standard deviation of blank) was the highest with the pure buffer. SNR values were lower in the rest of media, while their differences were statistically insignificant ($P = 0.40$, one-way ANOVA). The sample handling thus can be simplified by using plasma or whole blood; no additional process is needed to obtain serum (**Fig. S6**).

We further characterize the IBS assay using IL-3 spiked plasma samples. The limit of detection (LOD) was estimated using a standard formula: IL-3 concentration that generates analytical signal equal to 3-times standard deviation of blank samples.³³ From the titration experiments, we established the LOD of ~ 5 pg/mL for IBS (**Fig. 2D**), while similar measurements with ELISA required more than 100 pg/mL for reliable detection. In addition, the dynamic ranges (given by the ratio of the maximum and minimum concentrations over which the current can be recorded) of the IBS ($\sim 10^4$) span an order of magnitude larger than ELISA ($\sim 10^3$). Using matched controls (IgG beads) was important to compensate for background signals from sample-dependent, nonspecific binding.

The observed speed and high sensitivity of IBS could be attributed to its favorable assay configurations: i) IBS has faster kinetics in target capture as magnetic beads are suspended in the entire sample volume (*i.e.*, 3-dimensional diffusion). Plate-based ELISA, in contrast, is based on 1-dimensional diffusion of target molecules to the capture surface, requiring longer incubation time. ii) In IBS, the signal generating analyte can be effectively concentrated through magnetic enrichment, thereby enhancing the signal level.

Clinical study

We finally applied IBS to detect IL-3 in clinical samples. Plasma or serum samples were collected from patients with symptoms of systemic infection, inflammation, or both. We obtained 23 samples from septic patients and another 39 from non-septic patients (**Table S2**). All the blood samples of 23 patients evaluated in our clinical study were collected *during or before* surgery. The onset of sepsis was defined as circulation failure, thereby the beginning of catecholamine therapy. We split each sample into two aliquots, and used them for IBS and ELISA, respectively. Overall, we observed higher IL-3 level in septic patient samples (**Fig. 3A** and **Fig. S7**). IBS, however, better differentiated septic from non-septic patient groups (**Fig. 3B**), which can be attributed to its higher sensitivity than ELISA.

We next constructed a receiver operating characteristic (ROC) curve using IL-3 level as a predictor (**Fig. 3C**). The optimal [IL-3] cutoff that maximizes both sensitivity and specificity was 21.7 pg/mL. With this cutoff, the detection accuracy was 86.0%, the sensitivity 91.3%, and the specificity 82.4%. We applied the cross validation method to estimate the area under the curve (AUC). The AUC value was 0.91 ± 0.08 (95% confidence interval) for IBS, whereas ELISA yielded smaller AUC of 0.73 ± 0.15 (95% confidence interval). We also evaluated the accuracy of the diagnostic test with or without including other host factors (*e.g.*, sex, age). Adding these factors, along with IL-3 level, did not improve the detection accuracy, and the AUC value remained statistically identical ($P = 0.52$).

We further performed the survival analysis, testing the impact of IL-3 on organ failures. We hypothesized that IL-3 could be used as a biomarker to identify “patients at risk”. These patients may develop a systemic inflammatory reaction that often results in multiple organ failures and even death. We used a cohort of 25 admitted patients who had at least one surgery. Kaplan-Meier analysis showed that patients with IL-3 > 24 pg/mL are more prone to organ failures, thus confirming the significant association of IL-3 with organ failures ($P = 0.0001$ for Log-Rank test; hazard ratio, 8.092) (**Fig. 4A**). Patients with high blood levels of IL-3 (> 24 pg/mL) showed about 9-fold greater hazard of death than those with low levels ($P = 0.0138$ for Log-Rank test; hazard ratio: 8.783) (**Fig. 4B**).

CONCLUSIONS

We developed the point-of-care IBS system for fast, sensitive identification of sepsis in busy clinical settings. Our approach is based on emerging understanding on host response to infection. IL-3, a cytokine that activates proliferation of hematopoietic stem cells and progenitors,³⁴ has recently been identified as a key regulator during sepsis pathogenesis.¹⁷ IL-3 operates upstream of key cytokines including TNF α , IL-1 β and IL-6; high IL-3 level and can trigger a detrimental cytokine storm. Measuring IL-3 thus can give an early window to monitor immune responses through minimally invasive blood testing. Up to date, alternative serum biomarkers of sepsis have had fairly low accuracy (e.g., calcitonin, soluble uPAR), one of the reasons why there has been intense interest in identifying alternative, causally related markers.

The magneto-electrochemical sensing strategy developed here enables POC diagnostics: i) magnetic beads provides large surface area ($\sim 230\text{ mm}^2$) for target capture and an easy way to perform assay steps; ii) the analytical signal is read out by compact, rugged electronics. Applying the IBS prototype, we achieved rapid ($<1\text{ hr}$), highly sensitive ($<10\text{ pg/mL}$) IL-3 detection in human plasma samples. Directly sampled whole blood may also be used without preprocessing, which would better position the assay into most clinical workflows. The pilot clinical study supported the potential of IL-3 as a surrogate biomarker of sepsis: the accuracy was 86.0%, the sensitivity was 91.3%, and the specificity 82.4%. In comparison, procalcitonin (PCT) has been shown to have accuracies below 80%.³⁵ Because IBS is fast and consumes small amount of samples ($100\text{ }\mu\text{L}$), it can be readily adopted to track temporal changes of biomarkers. This capacity would aid in not only the timely diagnosis of acute septic shock, but also reliable prognostication assessment of the risk. Also, using the small amount of samples would be especially advantageous for detection of sepsis in new borns/infants as blood samples from preterm infants (with a blood volume of $<50\text{ mL}$) are limited in volume.^{36–38}

Several aspects of the current study could be improved. First, we envision creating a sepsis marker panel and expanding IBS for multiplexed detection. With the limited availability of clinical samples ($500\text{ }\mu\text{L}$ per patient), we focused on IL-3 detection, optimizing IBS and cross-validating its performance. Sepsis has complex pathophysiology of systemic nature, not limited to single organs.^{39, 40} Measuring multiple markers (e.g., IL-3, TNF α , IL-1 β , PCT, IL-6) would potentially enable even more robust characterization of host response, further improving diagnostic accuracy. As a platform technology, IBS would be easily scaled up for such measurements. Second, sample preparation steps will have to be automated to realize a “sample-in and answer-out” system. We expect that the use of magnetic beads, thereby magnetic actuation, would facilitate replacing current manual operations with automation. Third, the software for data logging should be upgraded to comply with patient privacy laws. Fully integrated, easy-to-use IBS will promote assay reproducibility and help collect large data set to rigorously validate biomarkers with clinical samples. With these developments, IBS would be a powerful clinical tool to enable early sepsis diagnosis and improve treatment outcomes.

METHODS AND EXPERIMENTAL

Construction of the IBS system. The integrated device ($10 \times 10 \times 2.5 \text{ cm}^3$) is composed of two parts: sensor unit and sample processing unit. The sensor unit consists of a custom-designed potentiostat, a microcontroller (Atmega328, Atmel Corporation), a digital-to-analog converter (DAC8552, Texas Instruments), and an analog-to-digital converter (ADC161S626, Texas Instruments) (**Fig. S3b and Table S1**). There are two operational amplifiers (AD8606, Analog Devices) in the potentiostat: one for maintaining the potential difference between the working electrode and the reference, and the other for converting low-level current to voltage. Other sensor components include a communication module (Bluefruit EZLink) for Bluetooth connection with external devices (*i.e.*, smartphones or laptops), disposable screen-printed gold electrodes (220AT, Metrohm), and a 9V battery. The device runs continuously for 3–4 hr with a fully charged battery. The estimated energy consumption of the reader is $\sim 0.05 \text{ mW}$, and the averaged noise level is $\sim 0.3 \text{ nA}$. The sample processing unit consists of a custom-built magnetic pipette, and disposable 0.2 mL 8-tube strips (USA Scientific).

Smartphone Application. Using Xcode, we created an iOS application to facilitate system operation and data recording. The application allows users to record patient information and measurement details (time stamps, current value, and estimated analyte concentration). The data is stored with cloud storage.

Antibody conjugation to magnetic beads. Five milligrams of magnetic beads coated with epoxy groups (Dynabeads M-270 Epoxy, Invitrogen) was suspended in 1 mL of 0.1 M sodium phosphate solution at room temperature for 10 min. The optimal reaction ratio between antibody and bead concentrations was found [$10 \text{ }\mu\text{g}$ (antibody) : 1 mg (bead)] based on the price-performance ratio (**Fig. S4**). The magnetic beads were separated from the solution with a permanent magnet and resuspended in 100 μL of the same solution. One hundred micrograms of antibodies against IL-3 (R&D systems) or control IgG (R&D systems) was added and mixed thoroughly. One hundred microliters of 3 M ammonium sulfate solution was added, and the whole mixture was incubated overnight at 4°C with slow tilt rotation. The conjugation reaction was carried out at $\text{pH} = 7$. The beads were washed twice with PBS solution and finally resuspended in 0.25 mL of PBS with 1% bovine serum albumin (BSA) to have the final bead concentration of 10^8 – $10^9/\text{mL}$.

IBS assay. Each well in the linear tray was preloaded with reagent. One hundred microliters of IL-3-spiked PBS solution or different biological fluids such as single donor plasma, single donor serum, and single donor whole blood (Innovative Research) was loaded to a well containing immunomagnetic beads ($5 \text{ }\mu\text{L}$, 5×10^6 beads). The mixture was incubated for 30 min (20°C) with occasional stirring with a magnetic pipette. Magnetic beads were collected with the magnet pipette, and sequentially transferred to two wells, each containing 100 μL PBS solution with 0.05% Tween-20 (PBS-T). The beads were then collected and transferred to a well containing 50 μL of biotinylated antibodies (R&D systems) diluted in 0.1% BSA solution. Following 10-min incubation (20°C), the beads were washed as described before, and transferred to a well containing 50 μL of streptavidin-conjugated HRP enzymes (Thermo-Fisher Scientific, 1:1000 diluted in 0.1% BSA solution). After 5-min incubation (20°C), the beads were washed and resuspended in a well containing 15 μL of PBS. Seven microliters of the prepared bead solution and 20 μL of UltraTMB substrate solution (Thermo-Fisher Scientific) were loaded on top of the electrode *via* using a conventional volume pipette. After 3 min, chronoamperometry measurement was started with the electrochemical sensor. The current levels in the range of 40–45 s were averaged.

Enzyme-linked immunosorbent assay (ELISA). We used the same antibodies as used in IBS, and followed the vendor-recommended protocol (Thermo-Fisher Scientific) for ELISA. IL-3 antibody (R&D systems) was diluted to 2 µg/mL concentration in PBS and added to the Maxisorp 96-well plate (Nunc) for overnight incubation at 4 °C. After being washed three times with PBS-T, 2% BSA in PBS blocking solution was added to the plate for 2 h incubation at room temperature. Subsequently, serial dilute standard or samples were added to each well for at least 2 h incubation at room temperature. After the samples were discarded and washed three times with PBS-T, biotinylated detection antibodies (0.4 µg/mL, diluted in 0.1% BSA solution) were added to each well and incubated at room temperature for 2 h. Unbound antibodies were washed with PBS-T three times. High sensitivity streptavidin–HRP molecules (1:5000 diluted in 0.1% BSA solution) were added to the each well for 30 min at room temperature. After being washed out with PBS, TMB solution to each well was added and incubate for 20 min, added equal volume of stopping solution (2 M H₂SO₄), and read the optical density at 450 nm. Along with TMB substrate, SuperSignal® ELISA Femto Maximum Sensitivity Substrate (Thermo-Fisher Scientific) was also used.

Clinical samples. This clinical SEPIL-3 study was approved by the local ethics committee (Trial-Code-Nr.: EK 308082013) on September, 19th 2013. Blood samples were collected in the interdisciplinary operative intensive care unit of the University Hospital of Erlangen, Germany. Study patients or their legal designees signed written informed consent. After blood collection, plasma of all study participants was immediately obtained by centrifugation, transferred into cryotubes, and stored at -80°C until further processing. Quantification of IL-3 in human plasma samples was performed using an enzyme linked immunosorbent assay kit (R&D Systems). One hundred microliters of patient sample was used for each IBS analysis.

Statistics. The Spearman correlation coefficient was used to quantify the correlations. Group differences were tested using unpaired t-test. All tests were two-sided, and a P value of <0.05 was considered statistically significant. The ROC curve was constructed using the IL-3 level as a predictor for sepsis. The level cutoff was selected using Youden's index, which maximizes the sum of sensitivity and specificity. For survival analysis, Log-Rank test was used to compare times-to-event (times-to-organ failure or death) between low and high IL-3 groups. Kaplan-Meier method was used to calculate the survival function with a minimal p-value approach for cutoff optimization. Hazard ratio was estimated using Cox Proportional Hazards model.

FIGURE CAPTIONS

Scheme 1. IL-3 mediated mechanism of sepsis. Peritoneal B1a cells are activated by pathogens and give rise to IL-3+ B cells (IRA, innate response activator). IL-3 acts on hematopoietic stem progenitor cells (HSPC) to promote the emergency generation of inflammatory leukocytes that are released into the circulation. This leads to an uncontrolled cytokine storm, multiple organ failure, and septic shock that may result in death.

Figure 1. Integrated biosensor for sepsis (IBS). (A) Assay schematic. IL-3 is captured on magnetic beads directly in plasma or whole blood and labeled antibodies. Electrical signal is generated through enzymatic reaction. The entire assay is performed using a portable device, and complete within <1 hour. HRP, horseradish peroxidase. Ab, antibody. (B) Magnetic kit for sample processing. A magnetic pipette was custom-built to facilitate the sample handling. The plunger mechanism allows for easy collection and release of magnetic beads. (C) The base-station, housing measurement electronics, docks with a smartphone and a multi-well tray. An electrode slides in to the system for electrical connection. A smartphone app provides an user-interface for the system control (via Bluetooth) and data upload to a cloud server. (D) Photo of the whole assay system.

Figure 2. Assay characteristics and optimization. (A) Electrical currents are generated on or near the electrode *via* TMB redox reaction catalyzed by HRP-coated magnetic beads. With 100 mV reduction potential, the current level reached a plateau within 1 min. The current difference between the IL-3 and IgG control samples (ΔI) was used as an analytical metric. (B) IL-3 extraction yields were compared under different incubation conditions: 15 min, 30 min, and 12 hrs. Thirty minute incubation was sufficient. (C) Signal-to-noise ratios (SNR) were measured in different media spiked with IL-3 of 1 ng/mL. SNR values were statistically identical among serum, plasma, and whole blood ($P = 0.40$, $n = 10$ –12, one-way ANOVA). (D) Varying concentrations of IL-3 were spiked into human plasma and assayed by IBS and ELISA. The IBS performed 7-times faster and 12-times more sensitive than ELISA. The IL-3 extraction time was 30 min for the IBS assay. All measurements were performed at least three times, and the data are displayed as mean $\pm$ SD.

Figure 3. IL-3 as a biomarker for sepsis detection. Patient samples (23 from septic and 39 from non-septic patients) were analyzed with the IBS assay. (A) A waterfall plot shows the IL-3 levels measured by the IBS system. Each column represents a different sample (red, septic; grey, non-septic). (B) IL-3 level was higher in septic patients than in non-septic controls ($P < 0.0001$, unpaired t-test). (C) A receiver-operation characteristic curve was constructed. The area under the curve (AUC) was 0.91 with IBS and 0.73 with ELISA. The optimum threshold value that maximized both sensitivity and specificity was [IL-3] = 21.7 pg/mL.

Figure 4. Organ failure and mortality analyses. IL-3 level could serve as a predictive marker for organ failure free (A) and overall patient survival (B). Log-Rank test was used to compare times-to-

1 event (times-to-organ failure or death) between low and high IL-3 groups. Kaplan-Meier method was
2 used to calculate the survival function with a minimal p-value approach for cutoff optimization.
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ASSOCIATED CONTENT

The Supporting Information is available free of charge on the ACS Publications website at DOI: . The supporting materials include IBS device exterior and interior, circuit schematic, IBS app user interface, optimization of bioconjugation, optimization of the IBS assay, IBS assay with whole blood, ELISA analysis, and device cost and assay cost.

The authors declare no competing financial interest.

AUTHOR INFORMATION

Corresponding Authors

*E-mail: rweissleder@mgh.harvard.edu

*E-mail: hlee@mgh.harvard.edu

Author Contributions

J.M, F.K.S., R.W., and H.L. conceived the research. J.M. performed the experiments. M.N. and G.F.W. collected the clinical samples. B.C. developed the device. J.M. and B.C. developed the smartphone app. J.M., J.P., H.I., C.M.C., R.W., and H.L. analyzed data. H.Z. performed statistical analysis. J.M., G.F.W., C.M.C, F.K.S., R.W., and H.L. wrote the manuscript.


Funding Sources

The research of the manuscript was supported in part by U.S. Department NIH grants R21-CA205322 (H.L.), R01-HL113156 (H.L.), K99-CA201248 (H.I.), R01-CA204019 (R.W.), R01-EB010011 (R.W.), R01-EB00462605A1 (R.W.), P01-CA069246 (R.W.), Liz Tilberis Award Fund (C.M.C); MGH scholar fund (H.L. and F.K.S.); Andrew L. Warshaw, M.D. Institute for Pancreatic Cancer Research (H.I.), Lustgarten Foundation (R.W.), and the National Research Foundation of Korea (NRF-2017M3A9B4025699, NRF-2017M3A9B4025709; H.L.).

REFERENCES

- (1) Singer, M.; Deutschman, C. S.; Seymour, C. W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G. R.; Chiche, J. D.; Coopersmith, C. M.; Hotchkiss, R. S.; Levy, M. M.; Marshall, J. C.; Martin, G. S.; Opal, S. M.; Rubenfeld, G. D.; van der Poll, T.; Vincent, J. L.; Angus, D. C. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* **2016**, *315*, 801-810.
- (2) Fleischmann, C.; Scherag, A.; Adhikari, N. K.; Hartog, C. S.; Tsaganos, T.; Schlattmann, P.; Angus, D. C.; Reinhart, K.; International, F. O. A. C. T. Assessment of Global Incidence and Mortality of Hospital-Treated Sepsis. Current Estimates and Limitations. *Am J Respir Crit Care Med* **2016**, *193*, 259-272.
- (3) van der Poll, T.; Opal, S. M. Host-Pathogen Interactions in Sepsis. *Lancet Infect Dis* **2008**, *8*, 32-43.
- (4) Iwashyna, T. J.; Ely, E. W.; Smith, D. M.; Langa, K. M. Long-Term Cognitive Impairment and Functional Disability Among Survivors of Severe Sepsis. *JAMA* **2010**, *304*, 1787-1794.
- (5) Hotchkiss, R. S.; Monneret, G.; Payen, D. Sepsis-Induced Immunosuppression: From Cellular Dysfunctions to Immunotherapy. *Nat Rev Immunol* **2013**, *13*, 862-874.
- (6) Leentjens, J.; Kox, M.; van der Hoeven, J. G.; Netea, M. G.; Pickkers, P. Immunotherapy for the Adjunctive Treatment of Sepsis: From Immunosuppression to Immunostimulation. Time for a Paradigm Change. *Am J Respir Crit Care Med* **2013**, *187*, 1287-1293.
- (7) Torio, C. M.; Andrews, R. M. *National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011: Statistical Brief #160*; Agency for Healthcare Research and Quality (US): Rockville (MD), 2006; pp 1-12.
- (8) Martin, G. S.; Mannino, D. M.; Moss, M. The Effect of Age on the Development and Outcome of Adult Sepsis. *Crit Care Med* **2006**, *34*, 15-21.
- (9) Seymour, C. W.; Gesten, F.; Prescott, H. C.; Friedrich, M. E.; Iwashyna, T. J.; Phillips, G. S.; Lemeshow, S.; Osborn, T.; Terry, K. M.; Levy, M. M. Time to Treatment and Mortality During Mandated Emergency Care for Sepsis. *N Engl J Med* **2017**, *376*, 2235-2244.
- (10) Whiles, B. B.; Deis, A. S.; Simpson, S. Q. Increased Time to Initial Antimicrobial Administration is Associated With Progression to Septic Shock in Severe Sepsis Patients. *Crit Care Med* **2017**, *45*, 623-629.
- (11) Garnacho-Montero, J.; Gutiérrez-Pizarraya, A.; Escoresca-Ortega, A.; Fernández-Delgado, E.; López-Sánchez, J. M. Adequate Antibiotic Therapy Prior to Icu Admission in Patients With Severe Sepsis and Septic Shock Reduces Hospital Mortality. *Crit Care* **2015**, *19*, 302.
- (12) Haydar, S.; Spanier, M.; Weems, P.; Wood, S.; Strout, T. Comparison of Qsofa Score and Sirs Criteria as Screening Mechanisms for Emergency Department Sepsis. *Am J Emerg Med* **2017**, *35*, 1730-1733.
- (13) Donadello, K.; Scolletta, S.; Covajes, C.; Vincent, J. L. Supar as a Prognostic Biomarker in Sepsis. *BMC Med* **2012**, *10*, 2.
- (14) Kibe, S.; Adams, K.; Barlow, G. Diagnostic and Prognostic Biomarkers of Sepsis in Critical Care. *J Antimicrob Chemother* **2011**, *66 Suppl 2*, ii33-40.
- (15) Reinhart, K.; Bauer, M.; Riedemann, N. C.; Hartog, C. S. New Approaches to Sepsis: Molecular Diagnostics and Biomarkers. *Clin Microbiol Rev* **2012**, *25*, 609-634.
- (16) Rauch, P. J.; Chudnovskiy, A.; Robbins, C. S.; Weber, G. F.; Etzrodt, M.; Hilgendorf, I.; Tiglaio, E.; Figueiredo, J. L.; Iwamoto, Y.; Theurl, I.; Gorbato, R.; Waring, M. T.; Chicoine, A. T.; Mouded, M.; Pittet, M. J.; Nahrendorf, M.; Weissleder, R.; Swirski, F. K. Innate Response Activator B Cells Protect Against Microbial Sepsis. *Science* **2012**, *335*, 597-601.
- (17) Weber, G. F.; Chousterman, B. G.; He, S.; Fenn, A. M.; Nairz, M.; Anzai, A.; Brenner, T.; Uhle, F.; Iwamoto, Y.; Robbins, C. S.; Noiret, L.; Maier, S. L.; Zönnchen, T.; Rahbari, N. N.; Schölch, S.; Klotzsche-von Ameln, A.; Chavakis, T.; Weitz, J.; Hofer, S.; Weigand, M. A.; Nahrendorf, M.; Weissleder, R.; Swirski, F. K. Interleukin-3 Amplifies Acute Inflammation and is a Potential Therapeutic Target in Sepsis. *Science* **2015**, *347*, 1260-1265.
- (18) Weber, G. F.; Chousterman, B. G.; Hilgendorf, I.; Robbins, C. S.; Theurl, I.; Gerhardt, L. M.; Iwamoto, Y.; Quach, T. D.; Ali, M.; Chen, J. W.; Rothstein, T. L.; Nahrendorf, M.; Weissleder, R.;

- Swirski, F. K. Pleural Innate Response Activator B Cells Protect Against Pneumonia Via a Gm-Csf-igm Axis. *J Exp Med* **2014**, *211*, 1243-1256.
- (19) Bentzer, P.; Fjell, C.; Walley, K. R.; Boyd, J.; Russell, J. A. Plasma Cytokine Levels Predict Response to Corticosteroids in Septic Shock. *Intensive Care Med* **2016**, *42*, 1970-1979.
- (20) Vashist, S. K.; Lippa, P. B.; Yeo, L. Y.; Ozcan, A.; Luong, J. H. Emerging Technologies for Next-Generation Point-of-care Testing. *Trends Biotechnol* **2015**, *33*, 692-705.
- (21) Wang, T.; Zhang, M.; Dreher, D. D.; Zeng, Y. Ultrasensitive Microfluidic Solid-Phase Elisa Using an Actuatable Microwell-Patterned Pdms Chip. *Lab Chip* **2013**, *13*, 4190-4197.
- (22) Kai, J.; Puntambekar, A.; Santiago, N.; Lee, S. H.; Sehy, D. W.; Moore, V.; Han, J.; Ahn, C. H. A Novel Microfluidic Microplate as the Next Generation Assay Platform for Enzyme Linked Immunoassays (Elisa). *Lab Chip* **2012**, *12*, 4257-4262.
- (23) Lee, B. S.; Lee, Y. U.; Kim, H. S.; Kim, T. H.; Park, J.; Lee, J. G.; Kim, J.; Kim, H.; Lee, W. G.; Cho, Y. K. Fully Integrated Lab-on-a-disc for Simultaneous Analysis of Biochemistry and Immunoassay From Whole Blood. *Lab Chip* **2011**, *11*, 70-78.
- (24) Tan, X.; Khaing Oo, M. K.; Gong, Y.; Li, Y.; Zhu, H.; Fan, X. Glass Capillary Based Microfluidic Elisa for Rapid Diagnostics. *Analyst* **2017**, *142*, 2378-2385.
- (25) García, M.; Orozco, J.; Guix, M.; Gao, W.; Sattayasamitsathit, S.; Escarpa, A.; Merkoçi, A.; Wang, J. Micromotor-Based Lab-on-chip Immunoassays. *Nanoscale* **2013**, *5*, 1325-1331.
- (26) Herrmann, M.; Roy, E.; Veres, T.; Tabrizian, M. Microfluidic Elisa on Non-Passivated Pdms Chip Using Magnetic Bead Transfer Inside Dual Networks of Channels. *Lab Chip* **2007**, *7*, 1546-1552.
- (27) Ohashi, T.; Mawatari, K.; Sato, K.; Tokeshi, M.; Kitamori, T. A Micro-Elisa System for the Rapid and Sensitive Measurement of Total and Specific Immunoglobulin E and Clinical Application to Allergy Diagnosis. *Lab Chip* **2009**, *9*, 991-995.
- (28) Weng, X.; Gaur, G.; Neethirajan, S. Rapid Detection of Food Allergens By Microfluidics Elisa-Based Optical Sensor. *Biosensors (Basel)* **2016**, *6*, 24.
- (29) Wang, S.; Ge, L.; Song, X.; Yu, J.; Ge, S.; Huang, J.; Zeng, F. Paper-Based Chemiluminescence Elisa: Lab-on-paper Based on Chitosan Modified Paper Device and Wax-Screen-printing. *Biosens Bioelectron* **2012**, *31*, 212-218.
- (30) Jeong, S.; Park, J.; Pathania, D.; Castro, C. M.; Weissleder, R.; Lee, H. Integrated Magneto-Electrochemical Sensor for Exosome Analysis. *ACS Nano* **2016**, *10*, 1802-1809.
- (31) Lin, H. Y.; Huang, C. H.; Park, J.; Pathania, D.; Castro, C. M.; Fasano, A.; Weissleder, R.; Lee, H. Integrated Magneto-Chemical Sensor for on-Site Food Allergen Detection. *ACS Nano* **2017**, *11*, 10062-10069.
- (32) Park, K. S.; Huang, C. H.; Lee, K.; Yoo, Y. E.; Castro, C. M.; Weissleder, R.; Lee, H. Rapid Identification of Health Care-Associated Infections With an Integrated Fluorescence Anisotropy System. *Sci Adv* **2016**, *2*, e1600300.
- (33) MacDougall, D.; Crummett, W. B. Guidelines for Data Acquisition and Data Quality Evaluation in Environmental Chemistry. *Anal Chem* **1980**, *52*, 2242-2249.
- (34) Chousterman, B. G.; Swirski, F. K.; Weber, G. F. Cytokine Storm and Sepsis Disease Pathogenesis. *Semin Immunopathol* **2017**, *39*, 517-528.
- (35) Wacker, C.; Prkno, A.; Brunkhorst, F. M.; Schlattmann, P. Procalcitonin as a Diagnostic Marker for Sepsis: A Systematic Review and Meta-Analysis. *Lancet Infect Dis* **2013**, *13*, 426-435.
- (36) Howie, S. R. Blood Sample Volumes in Child Health Research: Review of Safe Limits. *Bull World Health Organ* **2011**, *89*, 46-53.
- (37) Prosser, A.; Hibbert, J.; Strunk, T.; Kok, C. H.; Simmer, K.; Richmond, P.; Burgner, D.; Currie, A. Phagocytosis of Neonatal Pathogens By Peripheral Blood Neutrophils and Monocytes From Newborn Preterm and Term Infants. *Pediatr Res* **2013**, *74*, 503-510.
- (38) Sankar, M. J.; Agarwal, R.; Deorari, A. K.; Paul, V. K. Sepsis in the Newborn. *Indian J Pediatr* **2008**, *75*, 261-266.
- (39) Pierrakos, C.; Vincent, J. L. Sepsis Biomarkers: A Review. *Crit Care* **2010**, *14*, R15.
- (40) Marshall, J. C.; Vincent, J. L.; Fink, M. P.; Cook, D. J.; Rubenfeld, G.; Foster, D.; Fisher, C. J.; Faist, E.; Reinhart, K. Measures, Markers, and Mediators: Toward a Staging System for Clinical Sepsis. A Report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. *Crit Care Med* **2003**, *31*, 1560-1567.



Scheme 1. IL-3 mediated mechanism of sepsis. Peritoneal B1a cells are activated by pathogens and give rise to IL-3+ B cells (IRA, innate response activator). IL-3 acts on hematopoietic stem progenitor cells (HSPC) to promote the emergency generation of inflammatory leukocytes that are released into the circulation. This leads to an uncontrolled cytokine storm, multiple organ failure, and septic shock that may result in death.

161x53mm (300 x 300 DPI)




Figure 1. Integrated biosensor for sepsis (IBS). (A) Assay schematic. IL-3 is captured on magnetic beads directly in plasma or whole blood and labeled antibodies. Electrical signal is generated through enzymatic reaction. The entire assay is performed using a portable device, and complete within <1 hour. HRP, horseradish peroxidase. Ab, antibody. (B) Magnetic kit for sample processing. A magnetic pipette was custom-built to facilitate the sample handling. The plunger mechanism allows for easy collection and release of magnetic beads. (C) The base-station, housing measurement electronics, docks with a smartphone and a multi-well tray. An electrode slides in to the system for electrical connection. A smartphone app provides an user-interface for the system control (via Bluetooth) and data upload to a cloud server. (D) Photo of the whole assay system.

319x197mm (300 x 300 DPI)




Figure 2. Assay characteristics and optimization. (A) Electrical currents are generated on or near the electrode via TMB redox reaction catalyzed by HRP-coated magnetic beads. With 100 mV reduction potential, the current level reached a plateau within 1 min. The current difference between the IL-3 and IgG control samples (ΔI) was used as an analytical metric. (B) IL-3 extraction yields were compared under different incubation conditions: 15 min, 30 min, and 12 hrs. Thirty minute incubation was sufficient. (C) Signal-to-noise ratios (SNR) were measured in different media spiked with IL-3 of 1 ng/mL. SNR values were statistically identical among serum, plasma, and whole blood ($P = 0.40$, $n = 10-12$, one-way ANOVA). (D) Varying concentrations of IL-3 were spiked into human plasma and assayed by IBS and ELISA. The IBS performed 7-times faster and 12-times more sensitive than ELISA. The IL-3 extraction time was 30 min for the IBS assay. All measurements were performed at least three times, and the data are displayed as mean $\pm$ SD.

195x158mm (300 x 300 DPI)




Figure 3. IL-3 as a biomarker for sepsis detection. Patient samples (23 from septic and 39 from non-septic patients) were analyzed with the IBS assay. (A) A waterfall plot shows the IL-3 levels measured by the IBS system. Each column represents a different sample (red, septic; grey, non-septic). (B) IL-3 level was higher in septic patients than in non-septic controls ($P < 0.0001$, unpaired t-test). (C) A receiver-operation characteristic curve was constructed. The area under the curve (AUC) was 0.91 with IBS and 0.73 with ELISA. The optimum threshold value that maximized both sensitivity and specificity was [IL-3] = 21.7 pg/mL.

121x137mm (300 x 300 DPI)




Figure 4. Organ failure and mortality analyses. IL-3 level could serve as a predictive marker for organ failure free (A) and overall patient survival (B). Log-Rank test was used to compare times-to-event (times-to-organ failure or death) between low and high IL-3 groups. Kaplan-Meier method was used to calculate the survival function with a minimal p-value approach for cutoff optimization.

182x69mm (300 x 300 DPI)



Table of Contents

143x103mm (300 x 300 DPI)